Summary Methotrexate (MTX) shows consistent cytotoxicity for melanoma cells in vitro but it is ineffective in clinical use at equivalent concentrations in vivo. This apparent paradox has been investigated by cell culture techniques and results quantified by cell number. In an in vitro model of high dose MTX therapy followed by leucovorin rescue (HD-MTX-LCR) there was survival of both melanoma and choriocarcinoma cell lines but not of an acute lymphocytic leukaemia cell line. The 70H metabolite of MTX was identified by HPLC in plasma samples of melanoma patients treated by HD-MTX-LCR, in which MTX concentrations 10 -5M were maintained for 24 h. However, metabolism per se is unlikely to account for the lack of response to MTX clinically. In vitro 70H-MTX (10-7-10 -6M) was two orders of magnitude less cytotoxic for melanoma than MTX (0-9-10-8 M). The cellular accumulation of [3H]-MTX, using a rapid gradient centrifuge technique for separation of melanoma cells from medium, was reduced in the presence of 70H-MTX.
Reports of clinical results in patients with advanced malignant melanoma treated with high dose methotrexate (MTX) therapy suggest a poor rate of response (Fisher et al., 1979; Karakousis & Carlson, 1979) . These reports do not, however, give any details of plasma concentrations of MTX achieved or the period of time over which a high concentration was maintained. An apparent paradox to this picture of lack of response to MTX in vivo is the observation that murine melanoma cells in vitro are rapidly killed by relatively low (10-8 M to 10-9M) concentrations of the agent (Bostock et al., 1979) .
Possible explanations for these paradoxical findings in vivo and in vitro may include the differences between the MTX concentrations to which cells are exposed and the possibility that folinic acid rescue used routinely in vivo may salvage tumour cells as well as essential marrow and mucosal elements. Differences in MTX transport, and metabolism between melanoma cells in vivo and in vitro may also operate and the activity of intracellular dihydrofolate reductase, and the proportion of cells undertaking DNA synthesis at the time of exposure to methotrexate may also be important variables. The observation that dihydrofolate reductase is identical in certain MTX-resistant and -sensitive wild-type lines of PGl9 murine melanoma (Bostock et al., 1979) indicates that qualitative enzyme differences are not responsible for the acquired resistance in some melanoma mutants.
We have investigated these variables by a study in which three patients with advanced malignant melanoma resistant to other cytotoxic drugs were treated with high dose MTX. The plasma concentrations of MTX and MTX metabolites were measured throughout a 24 h period. The relationship of these in vivo metabolites to those found in the culture medium surrounding human and murine melanoma cell lines treated with MTX in vitro was established. The uptake of the drug by the cells in culture was also studied in order to determine whether there was competition by 70H-MTX for uptake of MTX. When these findings were established, the ability of leucovorin to rescue melanoma cells from MTX toxicity was investigated.
Materials and methods
Clinical studies Three patients, 2 males and 1 female, with histologically proven stage III malignant melanoma, were treated with high dose methotrexate given by 24 h infusion. Plasma MTX concentrations were monitored by an EMIT assay during the infusion, to give immediate levels to assist in patient management, and the rate of infusion adjusted to maintain the concentration above 10-6 M. This was achieved in all patients, with peak concentrations > 10-M being observed.
At the end of each infusion, calcium leucovorin was given i.v. at a dose of 30 mg, thereafter 19 mg was given at 6 hourly intervals until plasma MTX concentrations fell below 10-6 M. In all cases the patients urine was kept alkaline using sodium bicarbonate and a fluid load was given at the end of the infusion. Two of the patients had 2 courses, all at 3-weekly intervals. No clinical response was observed.
The same plasma samples were subsequently reanalysed by high pressure liquid chromatography (HPLC) in order to determine MTX free from interference and to quantify 70H-MTX and other metabolites, if any. All concentrations described in this paper were determined using the HPLC assay.
In vitro studies The following cell lines were kindly provided by the named individuals.
Human melanoma B8 (B0008) and B1O (BOO10) (Creasey et al., 1979) ; MEL57 (Dr. C. Sorg, Universitats Hautklinik, Miinster); MYJ 15.
ADLER and KOTLER (Drs Houghton and Lloyd, Memorial Sloan Kettering Cancer Center, USA).
Murine melanoma The MTX-sensitive strain of the PG19 cell line (Bostock et al., 1979) was used in comparative studies.
Human choriocarcinoma BeWo and JaR cell lines (Prof. K. Bagshawe and colleagues).
Human acute lymphoblastic leukaemia KM3 (Schneider et al., 1977) Preparation of 70H-MTX The 7OH-MTX used in these studies was prepared by a method based on that of Johns & Loo, 1967. The product was purified chromatographically to homogeneity using a column of DE52 cellulose, eluted with 0.6 M ammonium bicarbonate. The relevant pooled fractions were freeze-dried to remove the ammonium bicarbonate. The compound was stored sterile at -20°C in aqueous solution and diluted by complete culture medium to the required concentrations.
Analysis of culture medium HPLC was used to analyze the media obtained from cell cultures incubated in the presence of MTX and/or 70H-MTX over periods up to 11 days. The medium was deproteinised by heating for Omin in a boiling water bath, the flocculated protein removed by high speed centrifugation using a Beckman microfuge, and the resulting supernatant injected directly on to a 1Ocm x 4 mm (ID) column of Hypersil ODS (Shandon-Southern Ltd., Runcorn, Cheshire, UK) and eluted isocratically using a mobile phase consisting of methanol: 0.05 M phosphoric acid, 28:72 containing 0. 1% hexanesulphonic acid. Detection was at 307 nm in an 8 ,ul flowcell. The flow rate was 1 ml min 1 (Farid et al., 1983 (Breithaupt et al., 1982) and that samples obtained after 24 h contained 70H-MTX at concentrations exceeding that of MTX (Figure 1 ).
In vitro studies Effect of MTX and 70H-MTX on cell growth Cloned human malignant melanoma lines and a murine melanoma line were used to obtain dose-response profiles at different concentrations of MTX. Two types of profile were observed ( Figure  2 ) when the relative cell numbers (RCC) were plotted against the concentration of MTX in the medium. In the first group of profiles cell growth was arrested at a 50% RCC value of 10-8-10-9M MTX. This group comprised the cell lines PGl9, B16 (murine) B8, BIO, MEL57 and ADLER Time (h) (human). The acute lymphocytic leukemia line (ALL), KM3, gave a similar profile. A second type of profile, essentially flat, was found for human melanoma MYJ15. It is possible that differences in growth kinetics between the cell lines might explain these two types of dose-response profiles obtained for MTX. This was explored by measurement of cell-kill following different durations of exposure to 10 -5M MTX (Figure 3) . The similarity of the 3 melanoma profiles suggests that any differences in growth kinetics do not affect the dose-response profile and that the steeper line for MEL57 compared with B8 and BlO reflects the greater sensitivity of MEL57 to MTX observed in Figure 2 . Figure 3 also shows the time profile for KM3 (ALL) cells exposed to MTX. This profile is much steeper, indicating a greater sensitivity to MTX reflecting the in vivo sensitivity. Figure 4 shows dose-response profiles obtained with 70H-MTX for the melanoma cell lines B8, BlO, MEL57 and PG19. This metabolite is cytotoxic for both the human and murine melanomas but about two orders of magnitude less effective than MTX. yield the same metabolite profiles as MTX. Representative chromatograms obtained at 7 days from PG19 cells which metabolise both MTX and 70H-MTX, and from B1O cells which metabolise neither compound are shown in Figure 6 . In each experiment chromatograms from "control" cultures, incubated for the same time intervals in the absence of MTX and 70H-MTX showed only the peak marked "M". In each case the baseline was flat in the area of the metabolite peaks, at a detector sensitivity of 0.08 AUFS. Supplementation of culture extracts with MTX or 70H-MTX immediately prior to HPLC gave peaks eluting in the region of the profile assigned to the pure compound.
Survivalfollowing leucovorin-rescue of cells in vitro Figure 8 shows that the choriocarcinoma JaR and B8 melanoma were rescued by leucovorin and gave similar profiles. We Time (days) Figure 7 Rescue by leucovorin of human melanoma and choriocarcinoma cells from toxicity of MTX in vitro. 0-0 B1O melanoma plus leucovorin, 0-0 B1O melanoma minus leucovorin, * * JaR choriocarcinoma plus leucovorin, ] Ol JaR choriocarcinoma minus leucovorin. The in vitro rescue assay was used. Cells were exposed to 10-6M MTX for 24h and toxicity reversed in the cultures indicated (plus leucovorin). The remaining cultures were put through the same rescue procedure but no leucovorin was added (minus leucovorin). The in vitro rescue method was used. Cells were exposed to 10-6 M MTX for 24h. Toxicity was reversed and incubation continues for 7 days in the presence of leucovorin as shown on the abscissa.
did not find leucovorin-rescue using the BeWo choriocarcinoma. KM3 (ALL) cells showed a rescue profile similar to JaR and B8 cells. The critical nature of the molar ratio of MTX to leucovorin in vitro is illustrated by an experiment (data not shown) in which rescue by the standard leucovorin method was ineffective for B10 cells when the concentration of MTX was raised to 5 x l0-M from the concentration of 106M used in the experiments shown in Figure 7 . Discussion This is the first study of melanoma patients treated with MTX in which plasma concentrations of the drug have been accurately monitored and the accumulation of metabolities observed and recorded. The results of these studies demonstrate that the lack of response of melanoma to MTX therapy is not due to failure to achieve adequate plasma concentrations. The concentrations achieved in our patients compared well with those known to be effective in patients with other MTX-sensitive tumours (see Breithaupt et al., 1982) . In previous clinical studies of MTX therapy in melanoma, total doses of 2 g m 2 of MTX over 6 h were used (Karakousis & Carlson, 1979) rather than 1.5 g over 24 h in our study. It (Galivan, 1979) . There was no correlation between those melanoma cell lines which metabolised MTX and resistance or sensitivity to it.
We have shown (Figure 2 ) that MTX arrests cell division at a concentration of 10-8 M and that following exposure to 10 6M methotrexate for 24 h there was no recovery of cell division up to 11 days after removal of MTX (Figure 7) .
We have also demonstrated that leucovorin can rescue melanoma cells in culture from the toxicity of MTX. The concentrations used in our in vitro experiments correspond to those reported for murine ascitic tumours by Sirotnak et al. (1978) . These values might be expected to be found in vivo using a standard regime, from which it is clear that both melanoma and non-malignant cells could benefit from leucovorin-rescue. The fact that the choriocarcinoma JaR also responds to leucovorinrescue in vitro indicates that tetrahydrofolate-rescue is not unique to melanoma and therefore probably not the sole reason for the failure of MTX/leucovorin therapy in patients with melanoma. However KM3 (ALL) cells sensitive to MTX in vivo showed considerable time dependency in that they failed to respond to leucovorin-rescue following 8 h of exposure to MTX.
The failure to rescue KM3 (ALL) cells in our standard assay may be related to a more rapid cell cycle than the melanoma lines used. Clinically this would account for a larger fractional cell-kill before the concentration of 70H-MTX reached sufficient magnitude to interfere with cell-kill.
Our studies demonstrate competition by the major in vivo metabolite, 70H-MTX, for the uptake of MTX by melanoma in vitro. If this is mirrored in vivo, after 12h further uptake of MTX from the plasma would be inhibited by the higher concentrations of 70H-MTX. In conjunction with the response to leucovorin-rescue, the effect would be to expose melanoma cells to MTX for a much shorter period than suspected hitherto. This may go some way towards explaining why these particular tumours are non-responsive to the drug using current therapeutic protocols.
In summary we have shown that the nonresponse of melanoma cells in vivo is unlikely to be related to the plasma MTX concentration, or to the ability of these cells to metabolise it. The plasma profile and in vitro data suggest that after 12 h at least two factors may contribute to the continued survival of melanoma cells: the concentrations of 70H-MTX in plasma may be sufficient to inhibit the further uptake of MTX by these cells; secondly, leucovorin may rescue both viable melanoma cells and host tissue cells when current protocols are used. The additional possibility that melanoma in vivo is afforded protection from MTX cytotoxicity by as yet unidentified cell kinetic or biochemical mechanisms, such as the presence of salvaging metabolites (nucleosides or folates) remains to be investigated. 
